Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT00116701
NCT00116701
View on ClinicalTrials.gov
Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis
PHASE3
Completed
INTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
May 31, 2005
Conditions
Kidney Disease
Interventions
DRUG
Aranesp®
Sponsors
Lead Sponsor
Amgen
All Listed Sponsors
lead
Amgen
INDUSTRY
NCT00116701 - Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis | Biotech Hunter | Biotech Hunter